各位合作伙伴、行业同仁及天马（天吉）的全体员工：

时间是最伟大的书写者。过去几年，我们心怀梦想，脚踏实地，笃行不怠。从一纸蓝图到拔地而起，从潜心建设到全面投产——在常熟新材料产业园，一座占地80亩、总建筑面积达71,000平方米的全新现代化智造基地，现已全面投产。

这一刻，值得我们共同铭记。这是苏州天马医药集团与天吉生物发展史上的一座重要里程碑，更标志着我们在多肽与小分子药物全产业链布局上，正式迈入高质量发展的全新纪元。

蓄势三年，硬核智造全面跃升

作为深耕多肽制药领域二十六年的国家高新技术企业，我们将二十六年的技术积淀与制造经验，全部倾注于这座新基地之中。严格对标国际制药高标准，集研发、生产与质控于一体，一条全链条智造体系在此高效运转。

硬核产能，底气十足

4座国际标准API车间强势落成——3条多肽原料药产线、1条小分子原料药产线，配套4座GMP标准化综合制剂车间。多肽原料药年产能一举突破1500公斤，注射制剂年产能超过2亿支，其中冻干粉针与小容量注射剂分别突破1亿支。这不是一组冰冷的数字，而是我们服务全球市场的坚实承诺！

创新研发，驱动未来

超2000㎡现代化研发实验中心全面启用，多位海归博士领衔，硕博人才占比行业领先。从GLP-1到口服环肽，从前沿多肽到改良型新药，我们正在用持续的创新突破，为患者创造更多可能。

全球视野，品质为先

从原料入厂的第一道关卡，到成品放行的最后一刻，每一个环节都严格对标国际GMP规范。我们以全球标准要求自己，只为向世界各地的医药合作伙伴，稳定输出高品质产品与一站式CRO/CMO/CDMO技术服务。

感谢一路同行的你，新征程，我们携手共进！

Dear Partners, Industry Colleagues, and the Entire Team at Tianma & Tianji,

Time is the ultimate chronicler. Over the past few years, driven by a shared vision and unwavering dedication, we have turned a blueprint into reality. From meticulous construction to full-scale commercial production, our brand-new, state-of-the-art manufacturing campus—spanning 80 acres with a total floor area of 71,000 square meters in the Changshu New Materials Industrial Park—is now officially fully operational.  

This is a moment for us all to cherish. It marks a significant milestone in the corporate histories of Suzhou Tianma Pharma Group and Tianji Bio, signaling our entry into a new era of high-quality development in the comprehensive peptide and small-molecule supply chain.

Three Years in the Making: A Quantum Leap in Advanced Manufacturing

As a National High-Tech Enterprise with 26 years of deep cultivation in peptide pharmaceuticals, we have poured our quarter-century of technical accumulation and manufacturing expertise into this new facility. Strictly adhering to international pharmaceutical standards, this integrated campus seamlessly combines R&D, production, and quality control into a high-efficiency manufacturing ecosystem.

Robust Capacity, Unmatched Confidence

Four international-standard API workshops have been successfully established, featuring 3 peptide API production lines, 1 small-molecule API line, and 4 GMP-compliant comprehensive formulation workshops. Our annual peptide API production capacity has broken through 1,500 kilograms, while total injectable formulation capacity exceeds 200 million units—including over 100 million units each for lyophilized powder and small-volume injections. These are not just cold numbers; they represent our unwavering commitment to serving the global market!

Innovation-Driven, Fueling the Future

Our modernized R&D center, spanning over 2,000 square meters, is now fully operational. Led by seasoned overseas-returned Ph.D.s, our team boasts an industry-leading proportion of master's and doctoral talent. From GLP-1s to oral cyclic peptides, and from cutting-edge peptides to improved new drugs, we are driving continuous innovation to create more possibilities for patients worldwide.

Global Vision, Quality First

From the strict inspection of raw materials upon entry to the final product release, every step rigorously complies with international GMP standards. We hold ourselves to global benchmarks to ensure a stable supply of high-quality products and one-stop CRO/CMO/CDMO services for pharmaceutical partners around the globe.

Thank you to everyone who has walked this journey with us. On this new horizon, let's forge ahead together!